Navigation Links
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
Date:2/13/2008

ion

expense and related tax benefits of:

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

Cost of products and services

sold $(7,137) $(8,537) $(25,677) $(21,430)

Selling, general and

administrative (23,334) (25,262) (106,172) (121,822)

Research and development (13,128) (14,566) (58,101) (65,248)

Total pre-tax charges for

stock-based compensation

expense (43,599) (48,365) (189,950) (208,500)

Tax benefit 12,920 14,094 58,148 66,331

Stock-based compensation

expense, net of tax $(30,679) $(34,271) $(131,802) $(142,169)

Diluted earnings per share and diluted weighted average shares outstanding

for the three months and years ended December 31, 2007 and 2006 were

computed according to the provisions of FAS 123R.

(2) Includes charges of $(9,143)K recorded in December 2007 to write off

five finished lots of our Thymoglobulin inventory which did not meet

our specifications and $(11,773)K recorded in September 2007 to write

off four finished lots of our Thymoglobulin inventory which did not

meet our specifications.

(3) Includes a charge of $(64,000)K recorded in June 2007 to settle the

litigation related to the consolidation of our former tracking

stocks.

(4) Includes a charge of $(25,000)K for an upfront milestone payment paid

to Ceregene Inc. in June 2007 for the development and

commercialization of certain gene therapy products.

(5) Includes charges for the purchase of in-process research and

development of $(106,350)K related to our
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
2. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
3. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Delaware Court Approves Bioenvision, Genzyme Joint Petition
6. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
7. Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities
8. March of Dimes Delivers a New Look
9. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
11. Gleevec, the targeted cancer pill, delivers more good news to patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... King of Prussia, PA (PRWEB) October 22, 2014 ... Group, is recognized as an industry leader with over ... industry award winning team leader in the areas related ... In addition, Mr. Carlson is an Editorial Advisory Board ... Group Healthcare Council Educator. Blue Fin Group is ...
(Date:10/22/2014)... Two sisters in high school have developed ways to ... Krishen use electronic stethoscopes, which electronically amplify body sounds, ... or heartbeats. Ilina, a senior at Port Huron ... way to detect early lung damage in people exposed ... recorded one breath cycle each from 16 smokers, 25 ...
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is ... repair a damaged mitral valve as the heart continues ... by Abbott Vascular , is designed to treat ... in which the heart’s mitral valve leaflets fail to ... heart’s left ventricle into the left atrium. The heart ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... 21 Patient Safety Week was March 8-14. ... (1979), the pulse oximeter (1983) and the brain activity ... of these technological devices clearly improved patient safety. This ... a forward thinking, caring physician."Until now, I,ve never publicly ...
... MI based company, is researching and developing decontamination testing equipment ... use their extensive knowledge of cleaning and decontamination to develop repeatable ... ... (Vocus) April 21, 2009 -- Midbrook, Inc ., a Jackson, ...
... medical billing company, announces services that help medical professionals go paperless, ... the healthcare industry. , ... (PRWEB) April 21, 2009 ... upon the nation,s healthcare system to step up efforts to convert ...
... worldwide for self-directed home treatment of the most common cause of ... ... Edmonton, Canada (PRWEB) April 14, 2009 -- A new ... treatment of BPPV (Benign Paroxysmal Positional Vertigo), the most common ...
... 21 The University HealthSystem Consortium (UHC) today ... for employee satisfaction surveys and consulting services to ... agreement, which has 2 optional 1-year renewal periods, ... an extensive array of customized surveys and analyses ...
... the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory ... of supplemental new drug applications (sNDA) for SEROQUEL XR (quetiapine ... disorder (MDD) and generalized anxiety disorder (GAD).The Advisory Committee concluded: ... SEROQUEL XR was shown to be ...
Cached Medicine News:Health News:American Society of Anesthesiologists Recent Public Debate Comes to Dead End 2Health News:American Society of Anesthesiologists Recent Public Debate Comes to Dead End 3Health News:Midbrook Tackles Medical Decontamination 2Health News:Midbrook Tackles Medical Decontamination 3Health News:Dr. America Comes to Obama's Aid, Helps Doctors Digitize 2Health News:Canadian Medical Device Set to Speed Treatment and Cut Health Care Costs for Common Cause of Vertigo 2Health News:Canadian Medical Device Set to Speed Treatment and Cut Health Care Costs for Common Cause of Vertigo 3Health News:University HealthSystem Consortium Selects Morehead to Provide Employee Satisfaction and Consulting Services 2Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 2Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 3Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 4Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 5Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 6Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 7
(Date:10/22/2014)... -- Sanomedics International Holdings, Inc. (OTCQB: SIMH) – According ... Data Services, demand for thermometers is expected to grow ... demand for more accurate digital thermometers continues.  ... market for thermometers, and one of the companies serving ... Inc. Sanomedics International Holdings designs, develops, markets, ...
(Date:10/22/2014)... Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in ... drug for cancer, is designed for injection into solid ... oncology focus is on melanoma, breast cancer and cancers ... of PV-10 as a therapy for metastatic melanoma, and ... and psoriasis. This summer, the Company ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... 27, 2011 As a result of the flagging ... dangerous to their health, according to Consumer Reports, annual ... take a prescription medicine told pollsters they,d cut health-care ... or medical procedure, declining tests, or ordering cheaper drugs ...
... ( http://www.myprgenie.com ) --  Texans for Stem Cell Research ... panel of stem cell experts from Texas and around ... TSCR Second Annual Educational Symposium with a welcome address ... Health Affairs for The University of Texas System. The ...
Cached Medicine Technology:Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 2Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 3Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 4Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 5World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin 2World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin 3World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin 4World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin 5
Malaria device / strip (3 line, P.f/P.v Ag Test-pLDH)...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
BioSign® Malaria - Rapid Malaria Antigen Test...
Medicine Products: